CA-SYSDIG,-INC.
13.1.2021 13:02:34 CET | Business Wire | Press release
Sysdig, Inc., the secure DevOps leader, today announced findings from its Sysdig 2021 Container Security and Usage Report. While usage reveals organizations are shifting left by scanning images during the build phase, DevOps teams are still leaving their environments open to attack. The report also looks at trends, finding a 310 percent growth in container density since 2017.
The fourth annual report reveals how global Sysdig customers of all sizes and across industries are using and securing container environments. This real-world, real-time data provides insight into usage of the nearly one billion containers Sysdig customers run yearly, including security risks, container utilization, and services used. Read the Sysdig 2021 Container Security and Usage blog .
Among its findings, the report states that while 74 percent of customers are scanning before deployment, still more than half (58 percent) of containers are running as root. There are some containers that should run as root—security and system daemons for example—but this is a small portion of total containers. These risky configurations leave easy access to potentially compromise the system and access sensitive data. This finding stresses the need for security throughout the lifecycle of a container image—fixing vulnerabilities is not enough.
Highlights From the Report
Container density grows 170% since 2018
Over the past three years, the median number of containers-per-host more than doubled from 15 in 2018 to 41 today, indicating a growth in efficiency and a shift in cost savings as containers mature. This reveals a continued focus on optimization.
Prometheus continues to grow, 35% YoY
Open source adoption is broader than just Kubernetes as organizations are shifting toward Prometheus as the standard approach to monitoring container environments. The use of Prometheus metrics among Sysdig customers grew 35 percent year-over-year.
Docker down, containerd and CRI-O up 4X
In 2017, Docker represented 99 percent of containers in use at that time. Today, that number has fallen to 50 percent, down from 79 percent in October 2019. While Docker revolutionized containers, organizations are rapidly switching to newer runtimes like containerd and CRI-O.
21% of containers live less than 10 seconds
The ephemeral nature of containers is a unique efficiency advantage, yet it can be a challenge in managing issues around security, health, and performance. The short life of containers reaffirms the need for container-specific tools for security and monitoring. For example, organizations need metric collection with intervals of less than 10 seconds and a detailed record of what occurred when the container was alive.
“With the high-profile breaches we are seeing and the accelerated adoption of containers in production, the container security risk is now on the radar of CISOs. Across millions of containers that we have studied, it’s clear that organizations are shifting security left, but they are neglecting critical best practices,” said Suresh Vasudevan, chief executive officer of Sysdig. “Container security has to span the entire software development lifecycle. Until organizations fix risky configurations, protect their runtime environments, and invest in container forensics, we will see an increase in container security breaches. I expect we will see several high-impact breaches before we release our next report.”
Other Interesting Findings
- Falco, the open source runtime project for cloud-native environments created by Sysdig and donated to the CNCF, has seen a 300 percent increase in Docker Hub downloads over the last year.
- The use of golang increased to 66 percent, a 470 percent jump since last year.
- 63 percent of container images are replaced within two weeks or less, signifying a more frequent code deployment rate.
Learn More About this Report
- Download the full Sysdig 2021 Container Security and Usage Report .
- Download the infographic .
- Read the usage report blog .
- Join the webinar Real-World Insights: Dig into Sysdig’s Container Security and Usage Report on Jan. 21 at 10am PST to walk through the report with the author.
About Sysdig
Sysdig is driving the secure DevOps movement, empowering organizations to confidently secure containers, Kubernetes, and cloud services. With the Sysdig Secure DevOps Platform, cloud teams secure the build pipeline, detect and respond to runtime threats, continuously validate compliance, and monitor and troubleshoot cloud infrastructure and services. Sysdig is a SaaS platform, built on an open source stack that includes Falco and sysdig OSS, the open standards for runtime threat detection and response. Hundreds of companies rely on Sysdig for container and Kubernetes security and visibility. Learn more at www.sysdig.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005319/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
